Saturday, June 2 , 2007 | Oncolink

Oncolink Features

Find My Cancer Drug

Incidence of Human Papillomavirus (HPV)-Related Head and Neck Cancers in the U.S. from 1998-2003: Pre-HPV Vaccine Licensure Presenter: M. SaraiyaPresenter's Affiliation: Centers for Disease ControlType of Session: ScientificBackground The majority of head and neck cancers are related to alcohol and tobacco use (75%). However, human papillomavirus (HPV) has been...
Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) Presenter: A. ChaturvediPresenter's Affiliation: National Cancer InstituteType of Session: ScientificBackground Approximately 405,000 cases of head and neck cancers are diagnosed annually worldwide and approximately 40,000 are diagnosed...
Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) Scientific Session: Incidence Trends for Human Papillomavirus-Related (HPV-R) and Unrelated (HPV-U) Head and Neck Squamous Cell Carcinoma (HNSCC) in the United States (US) With the recent approval of a vaccine for HPV and a second approval pending,...
Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) Presenter: H.J. WaneboPresenter's Affiliation: Landmark Medical Center, Woonsocket, RIType of Session: ScientificBackground C225 (Cetuximab) is a monoclonal antibody directed against the epithelial growth factor receptor. The combination...
Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) Scientific Session: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG E2303) The...
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Scientific Session: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 ...
Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023. Presenter: Hanna, N.H.Presenter's Affiliation: Indiana University, Indianapolis, INType of Session: ScientificBackground Concurrent platinum-based chemotherapy and thoracic radiation treatment (RT) has become a standard of care in the treatment...
Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Presenter: C. MaegoldPresenter's Affiliation: University Medical Center, Mannheim, GermanyType of Session: ScientificBackground Bevacizumab (Avastin), a monoclonal antibody directed against the vascular endothelial growth factor receptor, has...
Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) Scientific Session: Randomized, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) ...
S0216: A Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC) Presenter: D. AdelsteinPresenter's Affiliation: Cleveland Clinic, Cleveland, OHType of Session: ScientificBackground Several phase III cooperative studies have established radiation therapy and concurrent single agent cisplatin as a clear...